CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
The SKC1 skin cancer clinical trial is now open to enrollment across Canada. This study aims to determine whether adding an immunotherapy drug prior to the standard surgical treatment for advanced skin cancer can improve patient outcomes. This study addresses a substantial unmet need in this patient population.
The MA33 (TROG 0701): A Randomised Phase III Study Of Radiation Doses And Fractionation Schedules For Ductal Carcinoma In Situ (DCIS) Of The Breast, has permanently closed.
The recently opened BR38 clinical trial is exploring whether adding stereotactic body radiotherapy (SBRT) to the current treatment of immunotherapy (with or without chemotherapy) can improve outcomes for patients with metastatic non-small cell lung cancer (NSCLC) and limited disease progression (oligoprogression).
Please be aware that Cohort F on IND.243: A Phase II Study of RP-6306 in Patients with Advanced Cancer has closed to accrual. As Cohort F was the last opened cohort, the IND.243 main study will also be closed. Please see the closure notice for additional details.
Please join us in welcoming Catherine Caule, who is the new patient representative supporting the Hematology Disease Site Committee.
Catherine is a long-time health advocate based in Ottawa, Ontario, and a 25-year member of the Lymphoma Support Group of Ottawa. After being diagnosed with advanced Hodgkin Lymphoma and participating in a clinical trial for relapsed disease, she became a passionate voice for patient-centered care and equitable access.
We are pleased to welcome Lesley Beaton as the new patient representative supporting the Gastrointestinal Disease Site Committee.
Lesley lives in Vancouver, BC, and brings both scientific and personal experience to her role. She spent more than three decades working in microbiology and regulatory compliance with Health Canada, gaining a scientific perspective on healthcare systems.
